Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jianghong Fan

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|June 2, 2018
Gastric emptying and intestinal appearance of nonabsorbable drugs phenol red and paromomycin in human subjects: A multi-compartment stomach approachPaulo Paixão, Marival Bermejo, Bart Hens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2020
FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast CancerMirat Shah, Suparna Wedam, Joyce Cheng, et al.
Molecular Pharmaceutics|July 25, 2017
Low Buffer Capacity and Alternating Motility along the Human Gastrointestinal Tract: Implications for in Vivo Dissolution and Absorption of Ionizable DrugsBart Hens, Yasuhiro Tsume, Marival Bermejo, et al.
Molecular Pharmaceutics|November 13, 2018
Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans-Part 2: Fed StatePaulo Paixão, Marival Bermejo, Bart Hens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2025
FDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgeryMichael I Barbato, Amy K Barone, Stephanie L Aungst, et al.
Molecular Pharmaceutics|October 30, 2018
Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans-Part 1: Fasted State ConditionsMarival Bermejo, Paulo Paixão, Bart Hens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2024
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung CancerMichael I Barbato, Diana Bradford, Yi Ren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2024
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, <i>ESR1</i>-Mutated Advanced or Metastatic Breast CancerMirat Shah, Hima Lingam, Xin Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2021
FDA Approval Summary: Selumetinib for Plexiform NeurofibromaDenise Casey, Suzanne Demko, Arup Sinha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2020
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast CancerPreeti Narayan, Tatiana M Prowell, Jennifer J Gao, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|June 2, 2018
Gastric emptying and intestinal appearance of nonabsorbable drugs phenol red and paromomycin in human subjects: A multi-compartment stomach approachPaulo Paixão, Marival Bermejo, Bart Hens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2020
FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast CancerMirat Shah, Suparna Wedam, Joyce Cheng, et al.
Molecular Pharmaceutics|July 25, 2017
Low Buffer Capacity and Alternating Motility along the Human Gastrointestinal Tract: Implications for in Vivo Dissolution and Absorption of Ionizable DrugsBart Hens, Yasuhiro Tsume, Marival Bermejo, et al.
Molecular Pharmaceutics|November 13, 2018
Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans-Part 2: Fed StatePaulo Paixão, Marival Bermejo, Bart Hens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2025
FDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgeryMichael I Barbato, Amy K Barone, Stephanie L Aungst, et al.
Molecular Pharmaceutics|October 30, 2018
Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans-Part 1: Fasted State ConditionsMarival Bermejo, Paulo Paixão, Bart Hens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2024
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung CancerMichael I Barbato, Diana Bradford, Yi Ren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2024
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, <i>ESR1</i>-Mutated Advanced or Metastatic Breast CancerMirat Shah, Hima Lingam, Xin Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2021
FDA Approval Summary: Selumetinib for Plexiform NeurofibromaDenise Casey, Suzanne Demko, Arup Sinha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2020
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast CancerPreeti Narayan, Tatiana M Prowell, Jennifer J Gao, et al.
Pageof 5